Search clinical trials for: IW-1701

Total 2007 results

Cyclerion Therapeutics

Completed

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

Healthy

United States
Cyclerion Therapeutics

Terminated

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Achalasia

United States
Cyclerion Therapeutics

Completed

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Healthy

United States
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD)

Sickle Cell Disease

United States, United Kingdom, Lebanon
Cyclerion Therapeutics

Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Healthy Volunteers

United States
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Follicular Lymphoma | Marginal Zone Lymphoma | DLBCL | CLL | MCL | Indolent Lymphoma | Richter's Transformation | SLL | Mediastinal Large B-cell Lymphoma | Aggressive Lymphoma

United States
Rigshospitalet, Denmark

Unknown

Optimization of Interval-training in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Denmark
Ironwood Pharmaceuticals, Inc.

Terminated

Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Dyspepsia | Functional Gastrointestinal Disorders

Belgium, Netherlands
Tisento Therapeutics
Children's Hospital of Philadelphia

Terminated

Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

MELAS

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

Healthy Volunteers

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

Healthy Volunteers

United States
Rigshospitalet, Denmark

Unknown

Interval-training and Appetite Regulation in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Denmark
Tisento Therapeutics

Terminated

IW-6463 Safety Study in Healthy Elderly Subjects

Other

Netherlands
Tisento Therapeutics

Completed

A Study of IW-6463 in Healthy Volunteers

Other

Netherlands
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

Diabetic Gastroparesis

United States
Ironwood Pharmaceuticals, Inc.

Recruiting

Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis | Bladder Pain Syndrome

United States
University of Colorado, Denver

Completed

Compression and Cold Therapy on the Post-Operative Shoulder

Postoperative Pain | Shoulder Pain

United States
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

Australia, Poland
Ironwood Pharmaceuticals, Inc.

Completed

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Gastroesophageal Reflux

United States
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

United States, Canada
University of Colorado, Denver

Completed

Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults (B-WELL)

Diabetes | Metabolic Syndrome | Aging

United States
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
Ironwood Pharmaceuticals, Inc.

Terminated

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

Canada, United States
Ironwood Pharmaceuticals, Inc.

Completed

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States
TG Therapeutics, Inc.

Completed

Study of TG-1801 in Subjects With B-Cell Lymphoma

B-Cell Lymphoma

Australia
Brainvectis, a subsidiary of Asklepios BioPharmaceutical...

Active, not recruiting

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Huntington Disease

France
TG Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center

Completed

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Assiut University

Not yet recruiting

Efficacy and Safety of Interwoven Self-Expandable Nitinol Stent for Femropopliteal Arterial Occlusive Diseases

Femoropopliteal Occlusive Disease

Egypt
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Apollomics Inc.

Recruiting

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Bioequivalence

New Zealand
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Active, not recruiting

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Locally Advanced/Metastatic HER2 Positive Solid Tumors

China, United States
Shanghai Chest Hospital

Not yet recruiting

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

NSCLC, Stage III
Atridia Pty Ltd.

Completed

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Ceragem Clinical Inc.

Not yet recruiting

CETIC-I (CEra Traction Improves Cervical Kyphosis -I)

Kyphosis | Cervical Kyphosis | Cervical Lordosis
Cyclerion Therapeutics

Completed

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers

Healthy

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Solid Tumor

China
Chinese PLA General Hospital

Recruiting

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

China
Coherus Biosciences, Inc.

Completed

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

Healthy

United States
Coherus Biosciences, Inc.

Completed

Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

Bioequivalence

United States
Cyclerion Therapeutics

Completed

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
Gilead Sciences

Withdrawn

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Coherus Biosciences, Inc.

Completed

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Immunity, Humoral

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States

3

Subscribe